Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
S413720-2mg | 2mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $31.90 | |
S413720-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $64.90 | |
S413720-10mg | 10mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $97.90 | |
S413720-50mg | 50mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $282.90 | |
S413720-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $391.90 |
S1P Receptor Agonists
Synonyms | Siponimod|1230487-00-9|BAF312 (Siponimod)|BAF-312|NVP-BAF312-NX|BAF312|Siponimod [INN]|Mayzent|Siponimod [WHO-DD]|1230487-85-0|UNII-RR6P8L282I|Siponimod [USAN]|RR6P8L282I|BAF-312(SiponiMod)|CHEMBL2336071|BAF 312|DTXSID40153847|1-[[4-[(E)-N-[[4-cyclohexyl- |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | BAF312 (Siponimod) is a next-generation S1P receptor agonist, selective for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, exhibits >1000-fold selectivity over S1P2, S1P3 and S1P4 receptors. Phase 3. |
Storage Temp | Store at -20°C,Argon charged |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Sphingosine 1-phosphate receptor Edg-1 agonist |
Product Description | Information Siponimod (BAF312) BAF312 (Siponimod) is a next-generation S1P receptor agonist, selective for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, exhibits >1000-fold selectivity over S1P2, S1P3 and S1P4 receptors. Phase 3. Targets S1P1 receptor ; S1P5 receptor 0.39 nM(EC50); 0.98 nM(EC50) In vitro BAF312 (Siponimod) is a potent and selective S1P receptor agonist, with EC50 of 0.39 nM and 0.98 nM for S1P1 and S1P5receptors, exhibits >1000-fold selectivity over S1P2, S1P3 and S1P4 receptors. BAF312 (1 h at 1 μM) promotes prominent internalization of S1P1 receptors by 91%. In vivo BAF312 effectively suppresses encephalomyelitis (EAE) in rats by internalizing S1P1 receptors, rendering them insensitive to the egress signal from lymph nodes. BAF312 significantly reduces clinical scores when dosed prophylactically or therapeutically in mice at 0.3 mg/kg. Cell Research(from reference) Cell lines:CHO Concentrations:~1 μM Incubation Time:1 h |
ALogP | 3.834 |
---|---|
Rotatable Bond | 10 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid |
---|---|
INCHI | InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+ |
InChi Key | KIHYPELVXPAIDH-HNSNBQBZSA-N |
Canonical SMILES | CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O |
Isomeric SMILES | CCC1=C(C=CC(=C1)/C(=N/OCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)/C)CN4CC(C4)C(=O)O |
PubChem CID | 44599207 |
Molecular Weight | 516.6 |
PubChem CID | 44599207 |
---|---|
CAS Registry No. | 1230487-00-9 |
ChEMBL Ligand | CHEMBL2336071 |
Reactome Reaction | R-HSA-9678854 |
Reactome Drug | R-ALL-9678745 |
DrugCentral Ligand | 5326 |
RCSB PDB Ligand | J8C |
GPCRdb Ligand | siponimod |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
G2228168 | Certificate of Analysis | May 31, 2022 | S413720 |
G2228171 | Certificate of Analysis | May 31, 2022 | S413720 |
G2228172 | Certificate of Analysis | May 31, 2022 | S413720 |
Solubility | Solubility (25°C) In vitro DMSO: 100 mg/mL warmed with 50ºC Water: bath (193.57 mM); Ethanol: 44 mg/mL warmed with 50ºC Water: bath (85.17 mM); Water: Insoluble; |
---|---|
Sensitivity | Hygroscopic |
DMSO(mg / mL) Max Solubility | 100 |
DMSO(mM) Max Solubility | 193.5733643 |
Water(mg / mL) Max Solubility | <1 |
Melt Point(°C) | 154 - 157°C |
1. Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, Pan S, Gray NS, Hinterding K, Cooke NG et al.. (2012) The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.. Br J Pharmacol, 167 (5): (1035-47). [PMID:22646698] |
2. Lewis ND, Haxhinasto SA, Anderson SM, Stefanopoulos DE, Fogal SE, Adusumalli P, Desai SN, Patnaude LA, Lukas SM, Ryan KR et al.. (2013) Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.. J Immunol, 190 (7): (3533-40). [PMID:23436932] |
3. O'Sullivan C, Schubart A, Mir AK, Dev KK. (2016) The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures.. J Neuroinflammation, 13 (3): (31). [PMID:26856814] |
4. Pan S, Gray NS, Gao W, Mi Y, Fan Y, Wang X, Tuntland T, Che J, Lefebvre S, Chen Y et al.. (2013) Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator.. ACS Med Chem Lett, 4 (3): (333-7). [PMID:24900670] |
5. Subei AM, Cohen JA. (2015) Sphingosine 1-phosphate receptor modulators in multiple sclerosis.. CNS Drugs, 29 (7): (565-75). [PMID:26239599] |
6. Gentile A, Musella A, Bullitta S, Fresegna D, De Vito F, Fantozzi R, Piras E, Gargano F, Borsellino G, Battistini L et al.. (2016) Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.. J Neuroinflammation, 13 (1): (207). [PMID:27566665] |
7. Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T et al.. (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.. Lancet, 391 (10127): (1263-1273). [PMID:29576505] |